SecBot SecBot
3 ·Filed Nov 12, 2026
WW

WWB

WINDWARD BIO GROUP AG
NEUTRAL
Impact 2/10
Horizonimmediate Processed4d 3h ago SEC0000947871-26-001015
Form 3: initial insider ownership statement
Actionable Insight • Neutral

Monitor for the issuer's IPO filing and any subsequent Form 4 filings by OrbiMed to track changes in its stake. The large preferred share position suggests significant pre-IPO investment.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$28.50
T+0 close · Nov 12, 2026 · via day close
Latest settled
+5.40%
T+1 · $30.04
Vs SPY
+7.32%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $28.50entry
  2. T+1 · 15h ago +5.40%α +7.32% · $30.04
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC filed Form 3 initial beneficial ownership reports for Windward Bio Group AG, disclosing aggregate holdings of approximately 5.7 million common shares (including shares underlying preferred stock and warrants) held through OrbiMed Private Investments IX, LP. The filing is a routine initial statement of ownership with no trading activity or change in position.

Key Facts

  • OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC filed Form 3 as reporting persons for Windward Bio Group AG.
  • OrbiMed Private Investments IX, LP holds 531,632 common shares, 3,561,936 common shares issuable upon conversion of Series A Preferred Shares, 1,611,008 common shares issuable upon conversion of Series B Preferred Shares, and warrants to purchase 216,668 common shares at $0.02 per share expiring May 12, 2036.
  • Total common share equivalent position is approximately 5,921,244 shares.
  • Series A and B Preferred Shares convert 1:1 into common shares immediately prior to the issuer's IPO closing.
  • David P. Bonita, a member of OrbiMed Advisors, serves on the issuer's board of directors.
  • The reporting persons disclaim beneficial ownership except for pecuniary interest.

Financial Impact

No financial impact; initial ownership disclosure with no transaction.

Risk Factors

  • No trading activity or change in position disclosed; filing is purely informational.
  • OrbiMed's board representation could lead to insider trading restrictions.

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0000947871-26-001015
Document: 0000947871-26-001015-index.html0000947871-26-001015
Document: 0000947871-26-001015.txt0000947871-26-001015

US Market Status

Market Closed · Opens Wed (11h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026